BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding BioAtla, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 39 | 43 | +4 |
| Shares | 13.2M | 13.3M | +180.1K (+1.4%) |
| Value | $5.21M | $9.19M | +$3.98M (+76.2%) |
New holders (10)
Institutions that held BioAtla, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 341,322 | $234.8K | 0.00% |
| Citadel Advisors LLC | 274,036 | $188.5K | 0.00% |
| Sheets Smith Investment Management | 67,000 | $46.1K | 0.03% |
| Citigroup Inc | 26,132 | $18.0K | 0.00% |
| NorthRock Partners, LLC | 20,783 | $14.3K | 0.00% |
| XTX Topco Ltd | 19,380 | $13.3K | 0.00% |
| Torrey Growth & Income Advisors | 14,687 | $10.1K | 0.00% |
| Two Sigma Securities, LLC | 13,761 | $9.47K | 0.00% |
| Jones Financial Companies LLLP | 2,325 | $1.55K | 0.00% |
| Barclays PLC | 183 | $126 | 0.00% |
Sold out (6)
Institutions that held BioAtla, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| ADAR1 Capital Management, LLC | 170,506 | $67.5K |
| Marshall Wace, LLP | 80,842 | $32.3K |
| Alpha Cubed Investments, LLC | 41,144 | $16.3K |
| National Asset Management, Inc. | 30,000 | $11.9K |
| Tower Research Capital LLC (TRC) | 23,316 | $9.23K |
| Two Sigma Advisers, LP | 14,100 | $5.58K |